Chemed Corporation $CHE Shares Acquired by HighTower Advisors LLC

HighTower Advisors LLC raised its stake in shares of Chemed Corporation (NYSE:CHE) by 6.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,452 shares of the company’s stock after purchasing an additional 145 shares during the quarter. HighTower Advisors LLC’s holdings in Chemed were worth $1,509,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of CHE. GAMMA Investing LLC increased its stake in Chemed by 131,200.8% during the 1st quarter. GAMMA Investing LLC now owns 166,752 shares of the company’s stock valued at $102,606,000 after purchasing an additional 166,625 shares in the last quarter. Freestone Grove Partners LP purchased a new position in shares of Chemed during the fourth quarter worth $61,664,000. Point72 Asset Management L.P. purchased a new position in shares of Chemed during the fourth quarter worth $54,587,000. Citadel Advisors LLC raised its holdings in shares of Chemed by 197.4% during the fourth quarter. Citadel Advisors LLC now owns 77,143 shares of the company’s stock worth $40,870,000 after purchasing an additional 51,206 shares during the last quarter. Finally, Nuveen LLC purchased a new position in shares of Chemed during the first quarter worth $30,527,000. Institutional investors and hedge funds own 95.85% of the company’s stock.

Insider Activity

In related news, Director George J. Walsh III bought 200 shares of the company’s stock in a transaction dated Monday, August 4th. The shares were acquired at an average price of $417.10 per share, for a total transaction of $83,420.00. Following the completion of the transaction, the director directly owned 3,523 shares in the company, valued at $1,469,443.30. This trade represents a 6.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Nicholas Michael Westfall sold 10,012 shares of Chemed stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $421.91, for a total transaction of $4,224,162.92. The disclosure for this sale can be found here. 3.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

CHE has been the subject of several recent research reports. Oppenheimer reduced their target price on shares of Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Wall Street Zen cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. Bank of America reduced their target price on shares of Chemed from $708.00 to $650.00 and set a “buy” rating for the company in a report on Monday, June 30th. Royal Bank Of Canada reduced their target price on shares of Chemed from $640.00 to $589.00 and set an “outperform” rating for the company in a report on Thursday, July 31st. Finally, Jefferies Financial Group assumed coverage on shares of Chemed in a report on Friday, July 25th. They set a “hold” rating and a $500.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $579.75.

Chemed Stock Performance

CHE opened at $460.0050 on Monday. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60. The company has a fifty day moving average of $472.64 and a two-hundred day moving average of $540.66. The stock has a market capitalization of $6.70 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.53 and a beta of 0.46.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, July 29th. The company reported $4.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.02 by ($1.75). Chemed had a net margin of 11.56% and a return on equity of 25.83%. The firm had revenue of $618.80 million during the quarter, compared to analysts’ expectations of $650.60 million. During the same period in the previous year, the firm posted $5.47 EPS. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. On average, equities research analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 29th. Stockholders of record on Monday, August 11th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.5%. This is a positive change from Chemed’s previous quarterly dividend of $0.50. The ex-dividend date is Monday, August 11th. Chemed’s dividend payout ratio (DPR) is 12.34%.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.